This project is designed to evaluate the molecular markers in patients that are undergoing radiotherapy in serum and urine. This work is prospective and hypothesis generating. In the past year we have initiated an international trial of patients with glioblastoma multiforme (GBM) to determine if urinary vascular endothelial growth factor (VEGF) or matrix metalloproteinase-2 (MMP-2) can help predict outcome. This past year we have worked on standardizing the collection procedures, analysis procedures, and the many biomolecules that could incorrectly alter the VEGF levels and we have published 2 manuscripts on specimen preparation and storage.
|Russo, Andrea L; Jedlicka, Kimberly; Wernick, Meredith et al. (2009) Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 15:4292-8|
|Brown, Aaron P; Wendler, David S; Camphausen, Kevin A et al. (2008) Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J Clin Oncol 26:3987-94|
|Hayward, Robert M; Kirk, Melissa J; Sproull, Mary et al. (2008) Post-collection, pre-measurement variables affecting VEGF levels in urine biospecimens. J Cell Mol Med 12:343-50|
|Baschnagel, Andrew; Wolters, Pamela L; Camphausen, Kevin (2008) Neuropsychological testing and biomarkers in the management of brain metastases. Radiat Oncol 3:26|
|Brown, Aaron P; Citrin, Deborah E; Camphausen, Kevin A (2008) Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 27:415-34|